Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
04 Oct 2020
Treatment with antivascular endothelial growth factor (anti-VEGF), along with regular monitoring, minimizes the risk of long-term vision loss in patients with neovascular age-related macular degeneration (AMD), a recent study has shown.
Stephen Padilla, 6 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Product Highlight - Xarelto

25 Jun 2020
The First & Only NOAC Approved for CAD/PAD1*
Xarelto, co-administered with ASA, is indicated for the prevention of atherothrombotic events in adult patients with CAD or symptomatic PAD at high risk of ischaemic events.2

In the COMPASS trial, Xarelto 2.5 mg bid + aspirin vs aspirin alone:
• -24% primary outcome: CV death, stroke or MI (p<0.001)3
• -23% all-cause mortality in CAD patients (p=0.0012)4
• -46% MALE and major amputations in PAD patients (p=0.0037)5
• No significant increase in the risk of most serious bleeding3
• Recommended by the 2019 ESC6 and ESVM7 Guidelines

ASA: acetylsalicylic acid; CAD: coronary artery disease; CV: cardiovascular; ESC: European Society of Cardiology; ESVM: European Society for Vascular Medicine; MALE: major adverse limb events; MI: myocardial infarction; NOAC: non-vitamin K oral anticoagulant; PAD: peripheral artery disease.

*As of Apr 1, 2020

References:
1. U.S. FDA Approves XARELTO® (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) [news release]. Titusville, NJ; October 11, 2018: Janssen Pharmaceuticals website. https://www.janssen.com/us-fda-approves-xareltor-rivaroxaban-reduce-risk-major-cardiovascular-events-patients-chronic. Accessed Apr 1, 2020.
2. Xarelto Hong Kong prescribing information.
3. Eikelboom JW, et al. N Engl J Med 2017;377:1319–1330.
4. Connolly SJ, et al. Lancet 2017; doi: 10.1016/S0140–6736(17)32458–3.
5. Anand SS, et al. J Am Coll Cardiol 2019;73:3271–80.
6. Neumann FJ, et al. European Heart Journal (2019) 00, 1-71. doi:10.1093/eurheartj/ehz425.
7. Frank U, et al. Vasa (2019), 48 (Supplement 102).


 

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
04 Oct 2020
Treatment with antivascular endothelial growth factor (anti-VEGF), along with regular monitoring, minimizes the risk of long-term vision loss in patients with neovascular age-related macular degeneration (AMD), a recent study has shown.
Stephen Padilla, 6 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.